SCHEMBL4533808

SCHEMBL4533808

Cc1nc2ccc(C=O)cc2s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.56
HTT P42858 4/20 0.53
ALDH1A1 P00352 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
NPC1 O15118 5/20 0.52
RAB9A P51151 5/20 0.52
HPGD P15428 2/20 0.52
TP53 P04637 1/20 0.52
MAPT P10636 1/20 0.52
PKM P14618 1/20 0.52
HSD17B10 Q99714 1/20 0.52
LDHA P00338 1/20 0.50
GAA P10253 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
KDM4E B2RXH2 1/20 0.46
DYRK3 O43781 3/20 0.44
CLK1 P49759 3/20 0.44
CLK2 P49760 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30644079 0.86 SMN1; SMN2 (0.56) SMN1; SMN2HTTALDH1A1TDP1NPC1
SCHEMBL2963197 0.86 SMN1; SMN2 (0.56) SMN1; SMN2HTTALDH1A1TDP1NPC1
SCHEMBL30224526 0.82 SMN1; SMN2 (0.56) SMN1; SMN2HTTALDH1A1TDP1NPC1
SCHEMBL12373172 0.80 CYP2A6 (0.42) SMN1; SMN2HTTALDH1A1NPC1RAB9A
SCHEMBL27936386 0.79 SMN1; SMN2 (0.53) SMN1; SMN2HTTALDH1A1TDP1NPC1
SCHEMBL10951998 0.79 CYP2A6 (0.41) SMN1; SMN2ALDH1A1TDP1NPC1RAB9A
SCHEMBL2275595 0.79 RAB9A (0.56) SMN1; SMN2HTTALDH1A1TDP1NPC1
SCHEMBL8170041 0.79 KMT2A (0.47) SMN1; SMN2HTTALDH1A1TDP1NPC1
SCHEMBL14858956 0.78 KEAP1 (0.59) SMN1; SMN2HTTALDH1A1TDP1NPC1
SCHEMBL25500478 0.78 NPC1 (0.41) SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4143185-B1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2025-10-29 EP disclosed
US-12398129-B2 Imidazolone derivatives as inhibitors of protein kinases in particular DYRK1A, CLK1 and/or CLK4 PERHA PHARMACEUTICALS (FR) 2025-08-26 US disclosed
US-20250091994-A1 RAS/RAF BINDING INHIBITOR COMPOUND NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) 2025-03-20 US disclosed
WO-2025039979-A1 PROTEIN ARGININE METHYLTRANSFERASE-5 INHIBITOR AND PHARMACEUTICAL USE THEREOF 江苏亚虹医药科技股份有限公司 2025-02-27 WO disclosed
EP-4457224-A1 HETEROCYCLIC COMPOUNDS BeiGene Switzerland GmbH (CH) 2024-11-06 EP disclosed
US-20240327417-A1 HETEROCYCLIC COMPOUNDS BEIGENE SWITZERLAND GMBH (CH) 2024-10-03 US disclosed
CN-118451073-A Heterocyclic compounds 百济神州有限公司 2024-08-06 CN disclosed
CN-117986262-A Condensed bicyclic compounds, preparation method and application thereof in medicine 江苏恒瑞医药股份有限公司 2024-05-07 CN disclosed
WO-2023218023-A1 THIAZOLOARYL-METHYL SUBSTITUTED CYCLIC HYDRAZINE-N-CARBOXAMIDE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2023-11-16 WO disclosed
WO-2023125681-A1 HETEROCYCLIC COMPOUNDS BEIGENE, LTD. (KY) 2023-07-06 WO disclosed
US-20100197869-A1 Aromatic hydrogenated polymers containing fluorine SOLVAY SOLEXIS S.P.A. (IT) 2010-08-05 US disclosed
US-20100069275-A1 Fluorinated lubricants SOLVAY SOLEXIS S.P.A. (IT) 2010-03-18 US disclosed
US-20090326154-A1 Additives for Halopolymers SOLVAY SOLEXIS S.P.A. (IT) 2009-12-31 US disclosed
US-7629483-B2 Peroxidic perfluoropolyethers SOLVAY SOLEXIS S.P.A. (IT) 2009-12-08 US disclosed
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES NOVARTIS AG 2009-10-22 US disclosed
US-20080275090-A1 AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS BRISTOL-MYERS SQUIBB COMPANY 2008-11-06 US disclosed
US-20080194881-A1 Copolymers having functional end groups of sulfonyl fluorides and acyl fluorides; macromer promoters useful for both condensation and addition polymerizations for elastomers and polymershaving a crystal structure; mechanical properties; lubricants for magnetic disks; adhesives SOLVAY SOLEXIS S.P.A. (IT) 2008-08-14 US disclosed
US-7371900-B2 Peroxidic perfluoropolyethers SOLVAY SOLEXIS S.P.A. (IT) 2008-05-13 US disclosed
US-7365229-B2 Peroxidic perfluoropolyethers SOLVAY SOLEXIS S.P.A. (IT) 2008-04-29 US disclosed
WO-2002060374-A2 BENZ-1,3-AZOLE DERIVATIVES AND THEIR USES AS HEPARANASE INHIBITORS INSIGHT STRATEGY AND MARKETING LTD (IL) 2002-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264406-A1 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES MET, ERBB2, ALK SMN1; SMN2 765/4885HTT 3764/4885ALDH1A1 973/4885
US-20250091994-A1 RAS/RAF BINDING INHIBITOR COMPOUND BRAF, RAF1, NRAS SMN1; SMN2 4832/4885HTT 4442/4885ALDH1A1 2352/4885
US-20240327417-A1 HETEROCYCLIC COMPOUNDS NFATC1, CD4, ACIN1 SMN1; SMN2 3398/4885HTT 4222/4885ALDH1A1 1006/4885
US-20080194881-A1 Copolymers having functional end groups of sulfonyl fluorides and acyl fluorides; macromer promoters useful for both condensation and addition polymerizations for elastomers and polymershaving a crystal structure; mechanical properties; lubricants for magnetic disks; adhesives FOXO1, FOXM1, F12 SMN1; SMN2 513/4885HTT 2792/4885ALDH1A1 1770/4885
US-12398129-B2 Imidazolone derivatives as inhibitors of protein kinases in particular DYRK1A, CLK1 and/or CLK4 CLK1, CLK2, CLK4 SMN1; SMN2 558/4885HTT 662/4885ALDH1A1 2571/4885
US-20080275090-A1 AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS P2RY1, P2RY11, P2RY2 SMN1; SMN2 3992/4885HTT 2964/4885ALDH1A1 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.